drugset
drugset / Trial / NCT00964873

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

NCT00964873 ↗

Phase 1 Completed 29 enrolled Synta Pharmaceuticals Corp.
NaSingle-groupOpen-labelTreatment

Summary

An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

Timeline

Start
2009-08
Primary completion
2010-12
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule — —

Indications

acute lymphoblastic leukemia acute myeloid leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive